CRF Health Selected for Oncology Trials
The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase.
CRF Health, a global provider of eCOA solutions, announced it has agreements with two top tier pharmaceutical companies to support Phase III trials in ovarian and breast cancer. The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase. The three studies-two in breast cancer and one in ovarian--will encompass 542 sites, 23 countries and almost 2,000 female trial participants, across the U.S, Europe and Asia Pacific.
Read the full release.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
